- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07784270
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-post: information.center@astrazeneca.com
Studieorter
-
-
-
CABA, Argentina, C1120AAC
- Research Site
-
CABA, Argentina, C1425HFA
- Research Site
-
Ciudad de Buenos Aires, Argentina, C1094AAD
- Research Site
-
Mendoza, Argentina, 5500
- Research Site
-
Ramos Mejía, Argentina, B1704ETD
- Research Site
-
Rosario, Argentina, S2000PBJ
- Research Site
-
San Nicolás, Argentina, B2900DMH
- Research Site
-
-
-
-
-
Botany, Australien, 2019
- Research Site
-
Helensvale, Australien, 4212
- Research Site
-
Kotara, Australien, 2289
- Research Site
-
Malvern, Australien, 3144
- Research Site
-
Maroubra, Australien, 2035
- Research Site
-
Waitara, Australien, 2077
- Research Site
-
-
-
-
-
Concepción, Chile, 4070196
- Research Site
-
Concepción, Chile, 4070060
- Research Site
-
Concepción, Chile, 4070566
- Research Site
-
Iquique, Chile, 1111442
- Research Site
-
Providencia, Chile, 7500504
- Research Site
-
Santiago, Chile
- Research Site
-
Santiago, Chile, 7691236
- Research Site
-
Santiago, Chile, 8331143
- Research Site
-
Santiago, Chile, 7510187
- Research Site
-
-
-
-
Alabama
-
Fairhope, Alabama, Förenta staterna, 36532
- Research Site
-
Huntsville, Alabama, Förenta staterna, 35801
- Research Site
-
-
Arizona
-
Mesa, Arizona, Förenta staterna, 85213
- Research Site
-
Phoenix, Arizona, Förenta staterna, 85044
- Research Site
-
Tucson, Arizona, Förenta staterna, 85715
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72205
- Research Site
-
-
California
-
Bakersfield, California, Förenta staterna, 93309
- Research Site
-
Gardena, California, Förenta staterna, 90247
- Research Site
-
Lincoln, California, Förenta staterna, 95648
- Research Site
-
Torrance, California, Förenta staterna, 90503
- Research Site
-
Walnut Creek, California, Förenta staterna, 94598
- Research Site
-
-
Florida
-
Coral Gables, Florida, Förenta staterna, 33134
- Research Site
-
Fleming Island, Florida, Förenta staterna, 32003
- Research Site
-
Fort Lauderdale, Florida, Förenta staterna, 33316
- Research Site
-
Ocoee, Florida, Förenta staterna, 34761
- Research Site
-
-
Georgia
-
Woodstock, Georgia, Förenta staterna, 30189
- Research Site
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60640
- Research Site
-
Melrose Park, Illinois, Förenta staterna, 60160
- Research Site
-
-
Kansas
-
Lenexa, Kansas, Förenta staterna, 66219
- Research Site
-
Newton, Kansas, Förenta staterna, 67114
- Research Site
-
-
Louisiana
-
Monroe, Louisiana, Förenta staterna, 71201
- Research Site
-
-
Maryland
-
Beltsville, Maryland, Förenta staterna, 20705
- Research Site
-
Lanham, Maryland, Förenta staterna, 20706
- Research Site
-
Oxon Hill, Maryland, Förenta staterna, 20745
- Research Site
-
-
Massachusetts
-
North Dartmouth, Massachusetts, Förenta staterna, 02747
- Research Site
-
-
Michigan
-
Farmington Hills, Michigan, Förenta staterna, 48336
- Research Site
-
-
Mississippi
-
Fayette, Mississippi, Förenta staterna, 39069
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Förenta staterna, 64111
- Research Site
-
St Louis, Missouri, Förenta staterna, 63141
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68114
- Research Site
-
Omaha, Nebraska, Förenta staterna, 68144
- Research Site
-
-
New Jersey
-
Eatontown, New Jersey, Förenta staterna, 07724
- Research Site
-
Somerset, New Jersey, Förenta staterna, 08873
- Research Site
-
Warren Township, New Jersey, Förenta staterna, 07059
- Research Site
-
-
North Carolina
-
Greensboro, North Carolina, Förenta staterna, 27408
- Research Site
-
Monroe, North Carolina, Förenta staterna, 28112
- Research Site
-
-
Ohio
-
Munroe Falls, Ohio, Förenta staterna, 44262
- Research Site
-
-
Pennsylvania
-
Scottdale, Pennsylvania, Förenta staterna, 15683
- Research Site
-
-
Tennessee
-
Franklin, Tennessee, Förenta staterna, 37067
- Research Site
-
Knoxville, Tennessee, Förenta staterna, 37938
- Research Site
-
-
Texas
-
DeSoto, Texas, Förenta staterna, 75115
- Research Site
-
El Paso, Texas, Förenta staterna, 79935
- Research Site
-
Houston, Texas, Förenta staterna, 77099
- Research Site
-
Midland, Texas, Förenta staterna, 79707
- Research Site
-
Pasadena, Texas, Förenta staterna, 77504
- Research Site
-
San Antonio, Texas, Förenta staterna, 78251
- Research Site
-
San Antonio, Texas, Förenta staterna, 78215
- Research Site
-
San Antonio, Texas, Förenta staterna, 78207
- Research Site
-
-
Virginia
-
Manassas, Virginia, Förenta staterna, 20110
- Research Site
-
Norfolk, Virginia, Förenta staterna, 23504
- Research Site
-
-
-
-
-
Bangalore, Indien, 560092
- Research Site
-
Indore, Indien, 452010
- Research Site
-
Kolkata, Indien, 700014
- Research Site
-
Nagpur, Indien, 440010
- Research Site
-
Pune, Indien, 411057
- Research Site
-
Pune, Indien, 411021
- Research Site
-
Siliguri, Indien, 734012
- Research Site
-
Visakhapatnam, Indien, 530002
- Research Site
-
-
-
-
-
Aira, Japan, 899-5421
- Research Site
-
Hachioji-shi, Japan, 192-0071
- Research Site
-
Izunokuni-shi, Japan, 410-2295
- Research Site
-
Kumamoto, Japan, 860-0833
- Research Site
-
Nagoya, Japan, 451-8511
- Research Site
-
Nagoya, Japan, 467-0806
- Research Site
-
Nerima-ku, Japan, 177-0051
- Research Site
-
Osaka, Japan, 540-0006
- Research Site
-
Osaka, Japan, 537-0014
- Research Site
-
Saga, Japan, 840-8571
- Research Site
-
Tanabe-shi, Japan, 646-8558
- Research Site
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T3R 1W9
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Y 3W2
- Research Site
-
-
New Brunswick
-
Moncton, New Brunswick, Kanada, E1G 1A7
- Research Site
-
-
Nova Scotia
-
Truro, Nova Scotia, Kanada, B2N 1L2
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8L 5G8
- Research Site
-
Markham, Ontario, Kanada, L3S 0A2
- Research Site
-
North York, Ontario, Kanada, M6B 3H7
- Research Site
-
Sarnia, Ontario, Kanada, N7T 4X3
- Research Site
-
Scarborough Village, Ontario, Kanada, M1R 0B1
- Research Site
-
Stoney Creek, Ontario, Kanada, L8J 3W2
- Research Site
-
Stouffville, Ontario, Kanada, L4A1H2
- Research Site
-
Toronto, Ontario, Kanada, M6G 1M2
- Research Site
-
Toronto, Ontario, Kanada, M4G3E8
- Research Site
-
-
Quebec
-
Joliette, Quebec, Kanada, J6E 6A9
- Research Site
-
Montreal, Quebec, Kanada, H4N 2W2
- Research Site
-
Montreal, Quebec, Kanada, H4J 1E3
- Research Site
-
Québec, Quebec, Kanada, G2J 0C4
- Research Site
-
Trois-Rivières, Quebec, Kanada, G9A 4P3
- Research Site
-
-
-
-
-
Beijing, Kina, 100050
- Research Site
-
Cangzhou, Kina, 061001
- Research Site
-
Changchun, Kina, 130011
- Research Site
-
Chengdu, Kina, 610072
- Research Site
-
Chengdu, Kina, 610021
- Research Site
-
Danyang, Kina, 212399
- Research Site
-
Ganzhou, Kina, 341000
- Research Site
-
Guangzhou, Kina, 510280
- Research Site
-
Huizhou, Kina, 516002
- Research Site
-
Huzhou, Kina, 313003
- Research Site
-
Lanzhou, Kina, 730000
- Research Site
-
Nanjing, Kina, 210009
- Research Site
-
Nanjing, Kina, 210008
- Research Site
-
Panjin, Kina, 124009
- Research Site
-
Suzhou, Kina, 215006
- Research Site
-
Xianyang, Kina, 712000
- Research Site
-
-
-
-
-
Bialystok, Polen, 15-481
- Research Site
-
Elblag, Polen, 82-300
- Research Site
-
Gdynia, Polen, 81-338
- Research Site
-
Katowice, Polen, 40-081
- Research Site
-
Katowice, Polen, 40-772
- Research Site
-
Krakow, Polen, 31-271
- Research Site
-
Krakow, Polen, 30-105
- Research Site
-
Legnica, Polen, 59-220
- Research Site
-
Lodz, Polen, 90-338
- Research Site
-
Lodz, Polen, 90-132
- Research Site
-
Poznan, Polen, 60-354
- Research Site
-
Radzionków, Polen, 41-922
- Research Site
-
Warsaw, Polen, 03-291
- Research Site
-
Warsaw, Polen, 00-719
- Research Site
-
Wroclaw, Polen, 53-673
- Research Site
-
-
-
-
-
Bratislava, Slovakien, 831 03
- Research Site
-
Bratislava, Slovakien, 83101
- Research Site
-
Bratislava, Slovakien, 83106
- Research Site
-
Košice, Slovakien, 040 01
- Research Site
-
Košice, Slovakien, 04022
- Research Site
-
Lučenec, Slovakien, 984 01
- Research Site
-
Námestovo, Slovakien, 02901
- Research Site
-
Prievidza, Slovakien, 97101
- Research Site
-
Rožňava, Slovakien, 048 01
- Research Site
-
Trebišov, Slovakien, 075 01
- Research Site
-
-
-
-
-
A Coruña, Spanien, 15006
- Research Site
-
Alzira, Spanien, 46600
- Research Site
-
Barcelona, Spanien, 08035
- Research Site
-
Ferrol, Spanien, 15405
- Research Site
-
Lleida, Spanien, 25198
- Research Site
-
Málaga, Spanien, 29010
- Research Site
-
Oviedo, Spanien, 33011
- Research Site
-
Segovia, Spanien, 40002
- Research Site
-
Seville, Spanien, 41010
- Research Site
-
Seville, Spanien, 41950
- Research Site
-
-
-
-
-
Chippenham, Storbritannien, SN15 2SB
- Research Site
-
Corby, Storbritannien, NN17 2UR
- Research Site
-
Corby, Storbritannien, NN18 9EZ
- Research Site
-
Dunfermline, Storbritannien, KY12 0SU
- Research Site
-
Hull, Storbritannien, HU3 2PA
- Research Site
-
Northwood, Storbritannien, HA6 2RN
- Research Site
-
-
-
-
-
Busan, Sydkorea, 48108
- Research Site
-
Daegu, Sydkorea, 42601
- Research Site
-
Daejeon, Sydkorea, 35233
- Research Site
-
Incheon, Sydkorea, 403-720
- Research Site
-
Seoul, Sydkorea, 08308
- Research Site
-
Seoul, Sydkorea, 06351
- Research Site
-
Seoul, Sydkorea, 01830
- Research Site
-
Seoul, Sydkorea, 143729
- Research Site
-
Seoul, Sydkorea, 150-713
- Research Site
-
Suwon, Sydkorea, 16247
- Research Site
-
-
-
-
-
Changhua, Taiwan, 500
- Research Site
-
Kaohsiung City, Taiwan, 80756
- Research Site
-
Taichung, Taiwan, 402
- Research Site
-
Taichung, Taiwan, 404
- Research Site
-
Taichung, Taiwan, 407219
- Research Site
-
Taichung, Taiwan, 433004
- Research Site
-
Tainan, Taiwan, 704
- Research Site
-
Tainan, Taiwan, 710
- Research Site
-
Taipei, Taiwan, 10002
- Research Site
-
Taipei, Taiwan, 11490
- Research Site
-
Zhubei, Taiwan, 302
- Research Site
-
-
-
-
-
Berlin, Tyskland, 10117
- Research Site
-
Berlin, Tyskland, 10629
- Research Site
-
Bochum, Tyskland, 44789
- Research Site
-
Bünde, Tyskland, 32257
- Research Site
-
Dresden, Tyskland, 01069
- Research Site
-
Frankfurt, Tyskland, 60596
- Research Site
-
Frankfurt, Tyskland, 60590
- Research Site
-
Freiburg im Breisgau, Tyskland, 79106
- Research Site
-
Göttingen, Tyskland, 37075
- Research Site
-
Hamburg, Tyskland, 20253
- Research Site
-
Hamburg, Tyskland, 20095
- Research Site
-
Hanover, Tyskland, 30159
- Research Site
-
Homburg, Tyskland, 66421
- Research Site
-
Jerichow, Tyskland, 39319
- Research Site
-
Karlsruhe, Tyskland, 76137
- Research Site
-
Leipzig, Tyskland, 04177
- Research Site
-
Magdeburg, Tyskland, 39110
- Research Site
-
Mainz, Tyskland, 55128
- Research Site
-
München, Tyskland, 80339
- Research Site
-
Offenbach, Tyskland, 63065
- Research Site
-
-
-
-
-
Balatonfüred, Ungern, 8230
- Research Site
-
Budapest, Ungern, 1036
- Research Site
-
Budapest, Ungern, 1138
- Research Site
-
Budapest, Ungern, 1132
- Research Site
-
Budapest, Ungern, 1024
- Research Site
-
Debrecen, Ungern, 4032
- Research Site
-
Debrecen, Ungern, 4031
- Research Site
-
Miskolc, Ungern, 3530
- Research Site
-
Nyíregyháza-Sóstóhegy, Ungern, 4481
- Research Site
-
Szeged, Ungern, 6725
- Research Site
-
Szolnok, Ungern, 5000
- Research Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Males & females (inclusive of all gender identities) age ≥18 years
- BMI ≥27 kg/m2
- Diagnosed with T2DM ≥90 days prior to Screening
- HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling)
- Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation
- History of at least one self-reported unsuccessful attempt to lose body weight in lifetime
Exclusion Criteria:
- Obesity primarily caused by other endocrine disorders
- Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening
Significant hepatobiliary disease and/or any of the following results at Screening:
- ALT ≥ 3.0 X ULN
- AST ≥ 3.0 X ULN
- TBL > 1.5 X ULN (except for cases of known Gilbert's Syndrome)
- Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation
- Use of insulin therapy for T2DM within 3 months prior to screening
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Placebo
Matchande placebo
|
Placebo matching IMP dose injected subcutaneously, once a week.
|
|
Experimentell: AZD6234 Dose 1
|
IMP injected subcutaneously, once a week.
Unit dose strength as per CSP.
|
|
Experimentell: AZD6234 Dose 2
|
IMP injected subcutaneously, once a week.
Unit dose strength as per CSP.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percent change in body weight from baseline at 68 weeks of treatment.
Tidsram: 68 weeks
|
To evaluate the effect of AZD6234 compared to placebo in percent body weight change
|
68 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Absolute change in weight (kg) from baseline at 68 weeks of treatment
Tidsram: 68 weeks
|
To evaluate the effect of AZD6234 compared to placebo on absolute change in weight
|
68 weeks
|
|
Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment
Tidsram: 68 weeks
|
To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 5%
|
68 weeks
|
|
Achievement of at least 10 % body weight loss from baseline at 68 weeks of treatment
Tidsram: 68 weeks
|
To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 10%
|
68 weeks
|
|
Change in haemoglobin A1C from baseline at 68 weeks of treatment
Tidsram: 68 weeks
|
To evaluate the effect of AZD6234 on haemoglobin A1C change
|
68 weeks
|
|
Change in waist circumference (cm) from baseline at 68 weeks of treatment
Tidsram: 68 weeks
|
To evaluate the effect of AZD6234 compared to placebo on waist circumference change
|
68 weeks
|
|
Percent change in triglycerides from baseline at 68 weeks of treatment
Tidsram: 68 weeks
|
To evaluate the effect of AZD6234 compared to placebo on triglycerides percent change
|
68 weeks
|
|
Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment
Tidsram: 68 weeks
|
To evaluate the effect of AZD6234 compared to placebo on systolic blood pressure change
|
68 weeks
|
|
Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset
Tidsram: 68 weeks
|
Body Composition Sub-study: To evaluate the effect of AZD6234 compared to placebo on body composition change in the DXA subset of participants
|
68 weeks
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- D8750C00012
- 2025 (U.S.S. NIH-anslag/kontrakt: Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
- 159494 (Registeridentifierare: IND Number)
- 2025-524616-11-00 (Ctis)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Tidsram för IPD-delning
Kriterier för IPD Sharing Access
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .